Market analysts with investment bank Robert W. Current Grail stockholders can also opt for additional cash and stock or a slice of revenue from any future Grail-related sales. Grail stockholders will get $3.5 billion in cash and $4.5 billion in shares in Illumina stock. The Galleri test uses Illumina sequencers to detect tumor-associated DNA modifications. Illumina estimates all forms of sequencing-based cancer testing, from screening the healthy to monitoring those who’ve been diagnosed, could be worth $75 billion by 2035. The company thinks such tests could be profitable, too. adults could benefit from routine blood tests that detect a wide swath of cancers. Illumina estimates that widespread adoption of the test could avoid 100,000 cancer-related deaths a year, and that 52 million U.S. Illumina expects to debut Galleri in the second half of 2021, and it believes there is a huge and growing market for such tests. The test accurately pinpointed the tumor’s location 93 percent of the time.įor those who didn’t develop cancer, Galleri produced a false positive result less than 1 percent of the time a low false positive rate means fewer false alarms for patients and doctors. Close to 2,500 of those in the study eventually developed one of more than 50 types of cancer, ranging from pancreatic to stomach to lung cancer.Īmong those who were later diagnosed with cancer, Galleri caught early signs of disease 44 percent of the time. That includes a study of nearly 6,700 participants published earlier this year. “We’ve seen some incredible early data about the performance of the test,” Febbo said. But Febbo says that what sets Grail apart is the amount of supporting evidence it has amassed.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |